• 1
    De Sarro A, Grasso S, Zappala M, et al. Convulsant effects of some xanthine derivatives in genetically epilepsy-prone rats. Naunyn Schmiedebergs Arch Pharmacol 1997;356: 4855.
  • 2
    Chu NS. Caffeine- and aminophylline-induced seizures. Epilepsia 1981;22: 8594.
  • 3
    Turski WA, Cavalheiro E, Ikonomidou C, et al. Effects of aminophylline and 2-chloroadenosine on seizures produced by pilocarpine in rats: morphological and electroencephalographic correlates. Brain Res 1985;361: 30923.
  • 4
    Ault B, Olney MA, Joyner JL, et al. Proconvulsant actions of theophylline and caffeine in the hippocampus: implications for the management of temporal lobe epilepsy. Brain Res 1987;426: 93102.
  • 5
    Cutrufo C, Bortot L, Giachetti A, et al. Differential effects of various xanthines on pentylenetetrazole-induced seizures in rats: an EEG and behavioral study. Eur J Pharmacol 1992;222: 16.
  • 6
    Albertson TE, Joy RM, Stark KG. Caffeine modification of kindled amygdaloid seizures. Pharmacol Biochem Behav 1983;19: 33944.
  • 7
    Dragunow M. Adenosine receptor antagonism accounts for the seizure-prolonging effects of aminophylline. Pharmacol Biochem Behav 1990;36: 7515.
  • 8
    Kaufman KR, Sachdeo RC. Caffeinated beverages and decreased seizure control. Seizure 2003;12(suppl 7):51921.
  • 9
    Antonaci F, Sances G, Manni R, et al. Epileptic seizure during aspirin and caffeine withdrawal in a drug induced headache. Funct Neurol 1996;11: 3337.
  • 10
    Scholfield CN. Depression of evoked potentials in brain slices by adenosine compounds. Br J Pharmacol 1978;63: 23944.
  • 11
    Smellie FW, Davis CW, Daly JW, et al. Alkylxanthines: inhibition of adenosine-elicited accumulation of cyclic AMP in brain slices and of phosphodiesterase activity. Life Sci 1979;24: 247582.
  • 12
    Katims JJ, Murphy KMM, Snyder SH. Xanthine stimulants and adenosine. In: CreeseI, eds. Stimulants: neurochemical, behavioral and clinical perspectives. New York : Raven Press, 1983: 6379.
  • 13
    Fredholm BB, Battig K, Holmen J, et al. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999;51: 83133.
  • 14
    Fastbom J, Pazos A, Palacios JM. The distribution of adenosine Al receptors and 5′-nucleotidase in the brain of some commonly used experimental animals. Neuroscience 1987;22: 81326.
  • 15
    Jarvis MF, Jacobson KA, Williams M. Autoradiographic localization of adenosine A1 receptors in rat brain using [3H]XCC, a functionalized congener of 1,3-dipropyhanthine. Neurosci Lett 1987;81: 6974.
  • 16
    Weber RG, Jones CR, Lohse MJ, et al. Autoradiographic visualization of A1 adenosine receptors in rat brain with [3H] 8-cyclopentyl-1,3-dipropylxanthine. J Neurochem 1990;54: 134453.
  • 17
    Fredholm BB, Hedqvist P. Modulation of neurotransmission by purine nucleotides and nucleosides. Biochem Pharmacol 1980;29: 163545.
  • 18
    Dragunow M, Goddard GV, Laverty R. Is adenosine an endogenous anticonvulsant? Epilepsia 1985;26: 4807.
  • 19
    Dunwiddie TV. Endogenously released adenosine regulates excitability in the in vitro hippocampus. Epilepsia 1980;21: 5418.
  • 20
    Dunwiddie TV, Hoffer BJ, Fredholm BB. Alkylxanthines elevate hippocampal excitability: evidence for a role of endogenous adenosine. Naunyn Schmiedebergs Arch Pharmacol 1981;316: 32630.
  • 21
    Snyder SH, Katims JJ, Annau Z, et al. Adenosine receptors and behavioral actions of methylxanthines. Proc Natl Acad Sci U S A 1981;78: 32604.
  • 22
    Stone TW. Physiological roles for adenosine and adenosine 5′-triphosphate in the nervous system. Neuroscience 1981;6: 52355.
  • 23
    Lee KS, Schubert P, Heinemann U. The anticonvulsive action of adenosine: a postsynaptic, dendritic action by a possible endogenous anticonvulsant. Brain Res 1984;321: 1604.
  • 24
    Gilbert RM. Caffeine consumption. In: SpillerGA, ed. The methylxanthine beverages and foods: chemistry, consumption, and health effects. New York : Alan R. Liss, 1984: 185213.
  • 25
    Debry G. Coffee and health. Paris : John Libbey, 1994: 1538.
  • 26
    Barone JJ, Roberts HR. Caffeine consumption. Found Chem Toxicol 1996;34: 11929.
  • 27
    Viani R. Caffeine consumption. Proc Caffeine Workshop. Bangkok : Thai FDA and ILSI, 1996.
  • 28
    Conlay LA, Conant JA, DeBros F, et al. Caffeine alters plasma adenosine levels. Nature 1997;389: 136.
  • 29
    Racine RJ. Modification of seizure activity by electrical stimulation, II: motor seizure. Electroencephalogr Clin Neurophysiol 1972;32: 28194.
  • 30
    Turski WA, Czuczwar SJ, Kleinrok Z, et al. Cholinomimetics produce seizures and brain damage in rats. Experientia 1983;39: 140811.
  • 31
    Arida RM, Scorza FA, Peres CA, et al. The course of untreated seizures in the pilocarpine model of epilepsy. Epilepsy Res 1999;34: 99107.
  • 32
    Leite JP, Bortolotto ZA, Turski L, et al. Spontaneous recurrent seizures in rats: an experimental model of partial epilepsy in rats. Neurosci Biobehav Rev 1990;14: 5117.
  • 33
    Mello LEAM, Cavalheiro EA, Babb TL, et al. Circuit mechanisms of seizures in the pilocarpine model of chronic epilepsy: cell loss and mossy fiber sprouting. Epilepsia 1993;34: 98595.
  • 34
    Brandt C, Glien M, Potschka H, et al. Epileptogenesis and neuropathology after different types of status epilepticus induced by prolonged electrical stimulation of the basolateral amygdala in rats. Epilepsy Res 2003;55: 83103.
  • 35
    Rigoulot MA, Koning E, Ferrandon A, et al. Neuroprotective properties of topiramate in the lithium-pilocarpine model of epilepsy. J Pharmacol Exp Ther 2004;308: 78795.
  • 36
    Dragunow M. Purinergic mechanisms in epilepsy. Prog Neurobiol 1988;31: 85108.
  • 37
    Eldridge FL, Paydarfar D, Scott SC, et al. Role of endogenous adenosine in recurrent generalized seizures. Exp Neurol 1989;103: 17985.
  • 38
    Freedholm BB, Lindström K. Autoradiographic comparison of the potency of several structurally unrelated adenosine receptor antagonists at adenosine A1 and A2A receptors. Eur J Pharmacol 1999;380: 197202.
  • 39
    Coffey CE, Figiel GS, Weiner RD, et al. Caffeine augmentation of ECT. Am J Psychiatry 1990;147: 57985.
  • 40
    Johansson B, Kuosmanen T, Fredholm BB. Long-term treatment with some methylxanthines decreases the susceptibility to bicuculline- and pentylenetetrazol-induced seizures in mice: relationship to c-fos expression and receptor binding. Eur J Neurosci 1996;295: 14754.
  • 41
    Georgiev V, Johansson B, Fredholm BB. Long-term caffeine treatment leads to a decreased susceptibility to NMDA-induced clonic seizures in mice without changes in adenosine A1 receptor number. Brain Res 1993;612: 2717.
  • 42
    Von Lubitz DK, Paul IA, Carter M, et al. Effects of N6-cyclopentyl adenosine and 8-cyclopentyl-1,3-dipropylxanthine on N-methyl-d-aspartate induced seizures in mice. Eur J Pharmacol 1993;249: 26570.
  • 43
    Bona E, Aden U, Fredholm BB, et al. The effect of long term caffeine treatment on hypoxic-ischemic brain damage in the neonate. Pediatr Res 1995;38: 3128.
  • 44
    Boulenger JP, Patel J, Post RM, et al. Chronic caffeine consumption increases the number of brain adenosine receptors. Life Sci 1983;32: 113542.
  • 45
    Rigoulot MA, Leroy C, Koning E, et al. Prolonged low-dose caffeine exposure protects against hippocampal damage but not against the occurrence of epilepsy in the lithium-pilocarpine model in the rat. Epilepsia 2003;44: 52935.
  • 46
    Fredholm BB, Dunwiddie TV. How does adenosine inhibit transmitter release? Trends Pharmacol Sci 1988;9: 1304.
  • 47
    Kukley M, Schwan M, Fredholm BB, et al. The role of extracellular adenosine in regulating mossy fiber synaptic plasticity. J Neurosci 2005;25: 283237.
  • 48
    Fastbom J, Fredholm BB. Effects of long-term theophylline treatment on adenosine-A1 receptors in rat-brain: autoradiographic evidence for increased receptor number and altered coupling to G-proteins. Brain Res 1990;507: 1959.
  • 49
    Frucht MM, Quigg M, Schwaner C, et al. Distribution of seizure among epilepsy syndromes. Epilepsia 2000;41(suppl 12):15349.
  • 50
    Jacobson KA, Von Lubitz DK, Daly JW, et al. Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol Sci 1996;17: 10813.